<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20060314184349+01'00'</creation_date><modification_date>D:20060314184349+01'00'</modification_date><initial_authorization>True</initial_authorization><pdf_file>EU-3-00-005_o_dec_0.pdf</pdf_file></head><body><section><header>en</header><p>commission of the european communities brussels, 18 october 2000 c(2000) 3025 final 
 not for publication</p></section><section><header>commission decision of 18 october 2000 
 relating to the designation of medicinal product gemtuzumab ozogamicin  as an orphan 
 medicinal product 
 en</header><p>only the english text is authentic</p><p> 2</p></section><section><header>commission decision of 18 october 2000 
 relating to the designation of medicinal product gemtuzumab ozogamicin as an orphan 
 medicinal product</header><p>only the english text is authentic the commission of the european communities, 
 having regard to the treaty establishing the european community, 
 having regard to regulation (ec) no 141/2000 of the european parliament and of the 
 council of 16 december 1999 on orphan medicinal products,
 1 and in particular article 5(8) thereof, 
 whereas: 
 (1)</p><p>an application concerning the medicinal product gemtuzumab ozogamicin was 
 submitted by the sponsor wyeth europa limited, and validated on 31 july 2000 under 
 article 5(4) of regulation (ec) no 141/2000. 
 (2)</p><p>the medicinal product gemtuzumab ozogamicin meets the designation criteria of 
 article 3(1) of the above-mentioned regulation. 
 (3)</p><p>the favourable opinion of the european agency for the evaluation of medicinal 
 products, adopted by the committee for orphan medicinal products on 13 september 
 2000, was received by the commission on 18 september 2000,</p><p>
 has adopted this decision:</p><p>
 article 1 the medicinal product gemtuzumab ozogamicin is hereby designated as an orphan medicinal product for the orphan indication: treatment of acute myeloid leukaemia. it shall be entered 
 in the community register of orphan medicinal products under the number eu/3/00/005.</p><p>
 1 oj l 18, 22.1.2000, p.1.</p><p> 3</p><p> 
 article 2 the european agency for the evaluation of medicinal products shall provide to all interested parties the opinion of the committee for orphan medicinal products referred to in this 
 decision. 
 article 3</p><p>this decision is addressed to the sponsor: wyeth europa limited, huntercombe lane south, taplow, maidenhead, berkshire, sl6 oph, united kingdom. 
 done at brussels, 18 october 2000</p><p>for the commission</p><p>erkki liikanen</p><p>
 member of the commission</p></section></body></xml>